First Midwest Bank Trust Division increased its position in shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) by 33.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,344 shares of the biopharmaceutical company’s stock after buying an additional 10,124 shares during the period. First Midwest Bank Trust Division’s holdings in Acadia Pharmaceuticals were worth $1,310,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. increased its stake in Acadia Pharmaceuticals by 120.0% in the second quarter. Winslow Evans & Crocker Inc. now owns 4,400 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 2,400 shares during the period. BlackRock Inc. increased its stake in Acadia Pharmaceuticals by 139.5% in the first quarter. BlackRock Inc. now owns 5,414 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 3,153 shares during the period. IFP Advisors Inc increased its stake in Acadia Pharmaceuticals by 28.7% in the first quarter. IFP Advisors Inc now owns 5,468 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 1,219 shares during the period. Bank of Montreal Can bought a new stake in Acadia Pharmaceuticals during the second quarter worth about $229,000. Finally, IBM Retirement Fund bought a new stake in Acadia Pharmaceuticals during the second quarter worth about $296,000. 92.10% of the stock is currently owned by institutional investors and hedge funds.
Shares of Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) traded down 2.72% during mid-day trading on Friday, hitting $31.81. 2,397,545 shares of the stock traded hands. The stock’s market cap is $3.63 billion. The stock has a 50-day moving average of $33.17 and a 200 day moving average of $32.69. Acadia Pharmaceuticals Inc. has a one year low of $16.64 and a one year high of $43.30.
Acadia Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by $0.14. Acadia Pharmaceuticals had a negative net margin of 131,066.23% and a negative return on equity of 64.25%. The business earned $0.97 million during the quarter, compared to analysts’ expectations of $0.71 million. During the same quarter in the previous year, the business posted ($0.39) EPS. The company’s quarterly revenue was up 96900.0% on a year-over-year basis. Equities analysts predict that Acadia Pharmaceuticals Inc. will post ($2.15) EPS for the current fiscal year.
A number of brokerages recently weighed in on ACAD. Needham & Company LLC restated a “buy” rating and issued a $49.00 price objective on shares of Acadia Pharmaceuticals in a report on Tuesday, July 26th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Acadia Pharmaceuticals in a report on Sunday, September 25th. JMP Securities restated a “buy” rating and issued a $45.00 price objective on shares of Acadia Pharmaceuticals in a report on Wednesday, August 10th. Cowen and Company restated an “outperform” rating and issued a $42.00 price objective on shares of Acadia Pharmaceuticals in a report on Tuesday, July 26th. Finally, Vetr cut shares of Acadia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.04 price objective for the company. in a report on Monday, June 6th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $45.80.
In other news, Director Bros. Advisors Lp Baker acquired 1,303,030 shares of the stock in a transaction on Wednesday, August 10th. The stock was bought at an average price of $33.00 per share, with a total value of $42,999,990.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edmund Harrigan acquired 1,000 shares of the stock in a transaction on Tuesday, August 16th. The stock was purchased at an average cost of $32.97 per share, with a total value of $32,970.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at $32,970. The disclosure for this purchase can be found here. 21.65% of the stock is currently owned by corporate insiders.
Acadia Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system disorders. The Company’s lead drug candidate, NUPLAZID (pimavanserin), is under development for the treatment of Parkinson’s disease psychosis (PDP).
Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acadia Pharmaceuticals Inc. (NASDAQ:ACAD).
Receive News & Ratings for Acadia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.